Pune, India -- (SBWIRE) -- 06/27/2018 -- Epilepsy is a group of neurological disorders characterized by seizures manifesting as brief, involuntary episodes of vigorous shaking of a part or complete body. The patient may experience loss or disturbance of consciousness and movements along with sensory or psychiatric disturbances. About 24 million people around the globe suffer from epilepsy with the global epilepsy drugs market reaching USD 3.7 billion in 2015. It is estimated that this market has the potential to reach USD 4.8 billion in 2022 representing a CAGR of 3.79%.

Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/2345 .

The Major Driving Factor for the Growth are:

Development of better tolerated third generation drugs
Increasing screening of patients, penetration and availability of drugs
Growth of geriatrics as they are affected more by epilepsy
Comparative lower competition in anti-epilepsy drugs as most drugs act by similar action. Thus, advent of a novel drug will make it a blockbuster with easy uptake and less marketing cost
Support for drug research and awareness created by social and government bodies
The constraints of the market are:
Loss of patents for a number of anti-epilepsy drugs such as Neurontin (2003) and Lyrica (scheduled in 2018)
Unknown origins and mechanism of action of epilepsy and concurrent lack of new novel acting drugs
Historical dominance of Gamma Aminobutyric Acid modulators and ion channel blockers, even though a sizeable segment of patients respond very poorly or none at all to these drugs
Associated side-effects, such as depression and suicide behavior, dizziness, fatigue, weight gain etc. of major class of drugs
High cost of clinical trials and extensive post market surveillance as it is difficult to separate cause and effect of drugs in epilepsy
Social stigma associated with epilepsy especially in the developing world
Key Players for Global Anti-Epilepsy Drugs Market

Pfizer, Inc., Johnson & Johnson, UCB Pharma Ltd., Abbott Laboratories, GlaxoSmithKline plc, Novartis International AG, Sanofi S.A., Shire Pharmaceuticals Limited and Cephalon Inc.

Segments for Global Anti-Epilepsy Drugs Market

Global Anti-Epilepsy Drugs market has been segmented on the basis of types of seizures, generation, and region.

Regional Analysis for Global Anti-Epilepsy Drugs Market

Globally, North America is the largest market for anti-epilepsy drugs. Europe is the second-largest market for anti-epilepsy drugs. The developing region especially Asia Pacific is accounting for major newer cases due to greater screening and better health care facilities distribution. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.

Get Prime Discount on Report @ https://www.marketresearchfuture.com/check-discount/2345 .

Some Brief Table of Contents of Report

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

TOC Continued…

Do You Have Specific Requirement? Ask To Our Experts@ https://www.marketresearchfuture.com/enquiry/2345 .

About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.